ScreenerHero
INDVIndivior PLC Ordinary Shares
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · indivior.com
38.64USD-1.02%Mkt Cap: 4.61B $P/E: 13.99

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap4.61B $
Enterprise Value4.75B $
Revenue (TTM)1.33B $
Gross Profit993.00M $
Net Income (TTM)210.00M $
Revenue/Share10.78 USD
Last Price38.64 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees827
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)13.99
P/E (Forward)7.74
PEG—
EV/EBITDA8.25
EV/Revenue3.57
P/S3.35
P/B-21.43
EPS (TTM)2.79
EPS (Forward)4.88
52W Range
38.680% of range40.00
52W High40.00 USD
52W Low38.68 USD
Profitability
Gross Margin80.15%
Oper. Margin46.94%
EBITDA Margin43.28%
Profit Margin16.95%
ROE-212.12%
ROA17.49%
Growth
Revenue Growth13.60%
Earnings Growth600.00%
Cash Flow & Leverage
Operating CF-27.00M $
CapEx (TTM)67.00M $
FCF Margin6.50%
FCF Yield1.88%
Net Debt287.00M $
Net Debt/EBITDA0.50
Balance Sheet
Debt/Equity-3.55
Current Ratio0.83
Quick Ratio0.59
Book Value/Sh-1.7630 USD
Cash/Share1.881 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 16, 2016
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)49.00 USD
Upside (mean)+26.8%
Target Range43.00 USD – 53.00 USD
$43.00+26.8% to mean$53.00
# Analysts4
Ownership
Shares Out.118.01M
Float116.04M
Insiders2.02%
Institutions98.94%
Short Interest
Short Ratio7.1d
Short % Float10.95%
Short % Out.9.22%
Shares Short10.88M
Short (prev mo.)10.78M
Technical
SMA 5039.58 (-2.4%)
SMA 20035.38 (+9.2%)
Beta1.14
S&P 52W Chg18.16%
Avg Vol (30d)1.61M
Avg Vol (10d)2.01M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—